{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:12:53Z","timestamp":1790881973390,"version":"4.1.0"},"reference-count":33,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2015,4,15]],"date-time":"2015-04-15T00:00:00Z","timestamp":1429056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Virol"],"published-print":{"date-parts":[[2015,4,15]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            To evaluate new vaccines when human efficacy studies are not possible, the FDA's \u201cAnimal Rule\u201d requires well-characterized models of infection. Thus, in the present study, the early pathogenic events of monkeypox infection in nonhuman primates, a surrogate for variola virus infection, were characterized. Cynomolgus macaques were exposed to aerosolized monkeypox virus (10\n            <jats:sup>5<\/jats:sup>\n            PFU). Clinical observations, viral loads, immune responses, and pathological changes were examined on days 2, 4, 6, 8, 10, and 12 postchallenge. Viral DNA (vDNA) was detected in the lungs on day 2 postchallenge, and viral antigen was detected, by immunostaining, in the epithelium of bronchi, bronchioles, and alveolar walls. Lesions comprised rare foci of dysplastic and sloughed cells in respiratory bronchioles. By day 4, vDNA was detected in the throat, tonsil, and spleen, and monkeypox antigen was detected in the lung, hilar and submandibular lymph nodes, spleen, and colon. Lung lesions comprised focal epithelial necrosis and inflammation. Body temperature peaked on day 6, pox lesions appeared on the skin, and lesions, with positive immunostaining, were present in the lung, tonsil, spleen, lymph nodes, and colon. By day 8, vDNA was present in 9\/13 tissues. Blood concentrations of interleukin 1ra (IL-1ra), IL-6, and gamma interferon (IFN-\u03b3) increased markedly. By day 10, circulating IgG antibody concentrations increased, and on day 12, animals showed early signs of recovery. These results define early events occurring in an inhalational macaque monkeypox infection model, supporting its use as a surrogate model for human smallpox.\n          <\/jats:p>\n          <jats:p>\n            <jats:bold>IMPORTANCE<\/jats:bold>\n            Bioterrorism poses a major threat to public health, as the deliberate release of infectious agents, such smallpox or a related virus, monkeypox, would have catastrophic consequences. The development and testing of new medical countermeasures, e.g., vaccines, are thus priorities; however, tests for efficacy in humans cannot be performed because it would be unethical and field trials are not feasible. To overcome this, the FDA may grant marketing approval of a new product based upon the \u201cAnimal Rule,\u201d in which interventions are tested for efficacy in well-characterized animal models. Monkeypox virus infection of nonhuman primates (NHPs) presents a potential surrogate disease model for smallpox. Previously, the later stages of monkeypox infection were defined, but the early course of infection remains unstudied. Here, the early pathogenic events of inhalational monkeypox infection in NHPs were characterized, and the results support the use of this surrogate model for testing human smallpox interventions.\n          <\/jats:p>","DOI":"10.1128\/jvi.03029-14","type":"journal-article","created":{"date-parts":[[2015,2,5]],"date-time":"2015-02-05T04:55:45Z","timestamp":1423112145000},"page":"4335-4344","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":41,"title":["Sequence of Pathogenic Events in Cynomolgus Macaques Infected with Aerosolized Monkeypox Virus"],"prefix":"10.1128","volume":"89","author":[{"given":"J. A.","family":"Tree","sequence":"first","affiliation":[{"name":"Microbiological Services, Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Hall","sequence":"additional","affiliation":[{"name":"Microbiological Services, Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Pearson","sequence":"additional","affiliation":[{"name":"Microbiological Services, Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rayner","sequence":"additional","affiliation":[{"name":"Microbiological Services, Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. A.","family":"Graham","sequence":"additional","affiliation":[{"name":"Microbiological Services, Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Steeds","sequence":"additional","affiliation":[{"name":"Microbiological Services, Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. R.","family":"Bewley","sequence":"additional","affiliation":[{"name":"Microbiological Services, Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. J.","family":"Hatch","sequence":"additional","affiliation":[{"name":"Microbiological Services, Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Dennis","sequence":"additional","affiliation":[{"name":"Microbiological Services, Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Microbiological Services, Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. D.","family":"Roberts","sequence":"additional","affiliation":[{"name":"Microbiological Services, Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. G. P.","family":"Funnell","sequence":"additional","affiliation":[{"name":"Microbiological Services, Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Vipond","sequence":"additional","affiliation":[{"name":"Microbiological Services, Public Health England, Porton Down, Salisbury, Wiltshire, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198011273032204"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.icb.7100033"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2009.11.030"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/0300985810378649"},{"key":"e_1_3_2_6_2","first-page":"37988","article-title":"New drug and biologics and drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible","volume":"67","author":"FDA","year":"2002","unstructured":"FDA. 2002. New drug and biologics and drug products; evidence needed to demonstrate effectiveness of new drugs when human efficacy studies are not ethical or feasible. Fed Regist 67:37988\u201337998.","journal-title":"Fed Regist"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.04.014"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.2217\/fvl.12.130"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01931-10"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature02331"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0804985105"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.07.030"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiq017"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00021-09"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01596-08"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.12.7845-7851.2005"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04295"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02525-10"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.010207-0"},{"key":"e_1_3_2_20_2","first-page":"4359","article-title":"Pathogenesis of fulminant monkeypox with bacterial sepsis after experimental infection with West African monkeypox virus in a cynomolgus monkey","volume":"7","author":"Nagata N","year":"2014","unstructured":"Nagata N, Saijo M, Kataoka M, Ami Y, Suzaki Y, Sato Y, Iwata-Yoshikawa N, Ogata M, Kurane I, Morikawa S, Sata T, Hasegawa H. 2014. Pathogenesis of fulminant monkeypox with bacterial sepsis after experimental infection with West African monkeypox virus in a cynomolgus monkey. Int J Clin Exp Pathal 7:4359\u20134370.","journal-title":"Int J Clin Exp Pathal"},{"key":"e_1_3_2_21_2","first-page":"169","volume-title":"In Smallpox and its eradication","author":"Fenner F","year":"1988","unstructured":"Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. 1988. The epidemiology of smallpox, p 169\u2013208. In Smallpox and its eradication. WHO, Geneva, Switzerland."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.22.2127"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012880"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3780373"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2012.00117"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.03481-12"},{"key":"e_1_3_2_27_2","volume-title":"Code of practice for the housing and care of animals used in scientific procedures","author":"United Kingdom Home Office","year":"1989","unstructured":"United Kingdom Home Office. 1989. Code of practice for the housing and care of animals used in scientific procedures. United Kingdom Home Office, London, United Kingdom. https:\/\/www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/228831\/0107.pdf."},{"key":"e_1_3_2_28_2","volume-title":"Guidelines on primate accommodation, care, and use","author":"National Committee for Refinement, Reduction, and Replacement (NC3Rs)","year":"2006","unstructured":"National Committee for Refinement, Reduction, and Replacement (NC3Rs). 2006. Guidelines on primate accommodation, care, and use. NC3Rs, London, United Kingdom."},{"key":"e_1_3_2_29_2","first-page":"B8","article-title":"Note on the particle size output of Collison nebulizers","volume":"45","author":"Gussman R","year":"1984","unstructured":"Gussman R. 1984. Note on the particle size output of Collison nebulizers. Am Ind Hyg Assoc J 45:B8\u2013B12.","journal-title":"Am Ind Hyg Assoc J"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-8502(73)90006-2"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0022172400041851"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0015615"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004123"},{"key":"e_1_3_2_34_2","first-page":"1","volume-title":"In Smallpox and its eradication","author":"Fenner F","year":"1988","unstructured":"Fenner F, Henderson DA, Arista I, Jezek Z, Ladnyi ID. 1988. The clinical features of smallpox, p 1\u201368. In Smallpox and its eradication. WHO, Geneva, Switzerland."}],"container-title":["Journal of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.03029-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JVI.03029-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T15:55:29Z","timestamp":1646495729000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JVI.03029-14"}},"subtitle":[],"editor":[{"given":"G.","family":"McFadden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,4,15]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,4,15]]}},"alternative-id":["10.1128\/JVI.03029-14"],"URL":"https:\/\/doi.org\/10.1128\/jvi.03029-14","relation":{},"ISSN":["0022-538X","1098-5514"],"issn-type":[{"value":"0022-538X","type":"print"},{"value":"1098-5514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,15]]},"assertion":[{"value":"2014-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-01-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-03-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}